[go: up one dir, main page]

WO2007073389A1 - Formes de dosage solides comprimées comprenant des médicaments de faible solubilité et procédé servant à les fabriquer - Google Patents

Formes de dosage solides comprimées comprenant des médicaments de faible solubilité et procédé servant à les fabriquer Download PDF

Info

Publication number
WO2007073389A1
WO2007073389A1 PCT/US2005/047260 US2005047260W WO2007073389A1 WO 2007073389 A1 WO2007073389 A1 WO 2007073389A1 US 2005047260 W US2005047260 W US 2005047260W WO 2007073389 A1 WO2007073389 A1 WO 2007073389A1
Authority
WO
WIPO (PCT)
Prior art keywords
sugar
drug
matrix
weight
partially amorphous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/047260
Other languages
English (en)
Inventor
Ilan Zalit
Mira Kopel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Teva Pharmaceuticals USA Inc
Original Assignee
Teva Pharmaceutical Industries Ltd
Teva Pharmaceuticals USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd, Teva Pharmaceuticals USA Inc filed Critical Teva Pharmaceutical Industries Ltd
Priority to PCT/US2005/047260 priority Critical patent/WO2007073389A1/fr
Priority to CNA2005800523342A priority patent/CN101340896A/zh
Priority to CA002626234A priority patent/CA2626234A1/fr
Publication of WO2007073389A1 publication Critical patent/WO2007073389A1/fr
Priority to IL190771A priority patent/IL190771A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Definitions

  • the present invention concerns a process to promote dissolution of poorly water soluble drugs in order to achieve rates of dissolution and absorption comparably similar to, or even faster than, the recent generation of technologies and products in the prior art.
  • solid dosage forms When solid dosage forms are taken orally, in many cases, the drug must dissolve in aqueous gastrointestinal fluids, for example in the patient's stomach, before the drug can exert a therapeutic effect.
  • the drug itself can be modified.
  • the physical form of the drug can be manipulated by various techniques to optimize the rate at which the drug dissolves.
  • the one most relevant to the present invention is particle size reduction.
  • the rate of dissolution of a solid may often depend upon the surface area that is exposed to the dissolving medium and since the surface area of a given mass of a substance is generally inversely proportional to the substance's particle size, reducing the particle size of a powder or granular substance may increase its dissolution rate.
  • particle size reduction often increases the dissolution rate of a particulate solid by increasing the surface area that is exposed to the dissolving medium.
  • particle size reduction is not always effective at increasing the dissolution rate of a drug from a compressed solid dosage form.
  • hydrophobic drugs have a strong tendency to agglomerate during the dosage form manufacturing process into larger particles with an overall decrease in effective surface area.
  • a drug that has ostensibly been milled to a fine particle size will sometimes display dissolution characteristics of a larger particle due to agglomeration or similar effect.
  • the new approaches of the pharmaceutical industry face two major barriers.
  • the first barrier is the technical /mechanical limitation of breaking the drug particles into the size of nano particles.
  • the second barrier is the stabilization of these small particles of the drug substance in the dosage form, whether they are in crystalline or amorphous form.
  • the present invention provides a process for making a pharmaceutical formulation of an active pharmaceutical ingredient (API), i.e., drug, having low aqueous solubility, the process comprising
  • the fixing step, i.e., step (A), of the above process of the invention is performed by heating a mixture of the drug, optionally pre-mixed or pre- granulated with at least one inactive excipient, and the at least one at least partially amorphous sugar followed by cooling.
  • the fixing step of the above process of the invention is performed by heating a mixture of the drug, optionally pre-mixed or pre-granulated with inactive excipient, and at least one sugar followed by cooling, wherein the at least one sugar is converted to the at least one at least partially amorphous sugar.
  • the heating is accompanied with mixing of the drug and the sugar.
  • step (A) The "sugar-drug matrix" obtained in the fixing step, i.e., step (A), of the above process preferably is a homogeneous dispersion of particles of the drug in the strong matrix.
  • the sugar-drug matrix may also be only partially homogeneous without departing from the spirit of the invention but preferably the sugar-drug matrix obtained in the fixing step will be substantially homogeneous which is understood to be of an even consistency by visual inspection.
  • Step (B) involves milling, preferably intensely, the "sugar-drag matrix" obtained in step (A), e.g., by using a comminuting mill exemplified by a FitzmillTM Communitor (Fitzpatrick "Knives" forward).
  • step (A) is performed as step (a) below and step (B) is performed as step (b) below, such that the embodiment comprises
  • At least one at least partially amorphous sugar which sugar is preferably substantially amorphous or entirely amorphous, in a Sugar-Drag ratio of from about 1.5:1 to about 10:1, preferably from about 2:1 to about 8:1 and more preferably from about 3:1 to about 6:1, wherein the amorphous sugar was prepared for example, by heating sucrose, glucose and water to a high temperature to form a mix and then cooling the mix,
  • a surface active agent e.g., polysorbate, glycerol monostearate and, preferably, sodium lauryl sulfate (SLS)
  • SLS sodium lauryl sulfate
  • a dispersing agent e.g., poloxamer, polysorbate, and preferably polyvinylpyrrolidone (PVP)
  • PVP polyvinylpyrrolidone
  • step (A) is performed by conducting steps (a')-(c') described below and step (B) is performed by conducting step (d') below, such that the second embodiment comprises:
  • step (d') milling, preferably intensely, the sugar-drug matrix obtained in step (c 5 ) optionally with a glidant, e.g., by using a comminution mill exemplified by a FitzmillTM Communitor ("Knives" forward) from The Fitzpatrick Company, or any similarly intensive milling machinery, to obtain a milled sugar-drug matrix as the pharmaceutical formulation, wherein the milled sugar-drug matrix comprises a powder.
  • a glidant e.g., by using a comminution mill exemplified by a FitzmillTM Communitor ("Knives" forward) from The Fitzpatrick Company, or any similarly intensive milling machinery, to obtain a milled sugar-drug matrix as the pharmaceutical formulation, wherein the milled sugar-drug matrix comprises a powder.
  • step (e'3) milling, preferably intensely, the cooled matrix obtained in step (e'2), e.g., by using a comminuting mill exemplified by a FitzmillTM Communitor
  • step (f ) optionally adding other pharmaceutically acceptable excipients, such as diluents, disintegrants, lubricants and glidants, to the blend obtained from step (d') or (e 5 ) in order to improve the handling and/or compression of the blend; and (g') tabletting the blend or filling the blend into capsules or sachets.
  • excipients such as diluents, disintegrants, lubricants and glidants
  • the present invention also provides a pharmaceutical formulation of the drug having low aqueous solubility prepared by anyone of the embodiments of the process of the invention.
  • Fig. 1 shows the dissolution data of fenofibrate tablets having a medium content of at least partially amorphous sugar (Formulation 11) and fenofibrate tablets having a high content of a different type of at least partially amorphous sugar (Formulation 12) of the invention compared with that of commercially available fenofibrate tablets (Tricor 145 mg and Tricor 160 mg), fenofibrate tablets made by conventional wet granulation (Formulaion 1), and fenofibrate tablets made by using fenofibrate and crystalline sugar (Formulation 13).
  • Fig. 2 shows the dissolution data of two fenofibrate blends having a high content of at least partially amorphous sugar (Formulations 4 and 7) according to the invention compared with that of commercially available fenofibrate formulations (Tricor 145 mg and Tricor 160 mg).
  • Fig. 3 shows the dissolution data of fenofibrate tablets 145 mg made with blends having a high ratio of sugar to drug in the "sugar-drug matrix" (Formulations 4 and 7) prepared according to the invention compared with that of the commercially available fenofibrate tablets (Tricor 145 mg and Tricor 160 mg).
  • Fig. 4 shows the dissolution data of fenofibrate tablets 145 mg having a high ratio of sugar to drug in the "sugar-drug matrix” using a "formulated granulate of fenofibrate” as the source of the "drug” in the process of preparing the "sugar-drug matrix” according to the invention compared with the dissolution data of the commercially available Tricor 145 mg and Formulation K-29740 ( bioequivalent to Tricor 160 mg, K-29740 being not a formulation of the invention).
  • a drug has "low aqueous solubility" or is “poorly soluble in water” if the water solubility of the un-ionized form of the drug is less than about 1% by weight, and typically less than about 0.1% or 0.01% by weight.
  • Such drugs include fenofibrate, bicalutamide, , atorvastatin, fluvastatin, , simvastatin, , paclitaxel, aripiprazole, glyburide, ezetimibe, oxcarbazepine , meloxicam, celecoxib, rofecoxib, valdecoxib and raloxifene.
  • At least partially amorphous sugar means that the sugar is partly or purely amorphous.
  • at least partially amorphous sugar encompasses situations where part of the sugar used is crystalline, either due to incomplete conversion from crystalline to amorphous form or due to re-crystallization of a portion of an amorphous sugar.
  • a sugar is "substantially amorphous” if the sugar is about 60-100 weight % such as about 60-95 weight %, more preferably about 80-99 weight %, and even more preferably about 90-99 weight %, amorphous.
  • Formulations of the invention can be made from amorphous sugar that has been prepared without using glucose.
  • strong matrix comprising at least one at least partially amorphous sugar refers to a dense and strong material comprising at least one at least partially amorphous sugar and having physical characteristics, such as rigidity, hardness and denseness, very similar to that of boiled sugar candy or hard sugar candy.
  • milling is used genetically to reflect methods of particle size reduction such as grinding of many types.
  • the term '"smooth" mixture' means that drug particles are evenly distributed in the sugar matrix and that the drug particles do not form lumps or agglomerates in the sugar-drug matrix.
  • the pharmaceutical formulation of the drug of low aqueous solubility it is important to control and define the weight ratio between the at least one at least partially amorphous sugar and the drug in the "sugar-drug matrix" well.
  • a high ratio of the at least one partially amorphous sugar to the drug in the "sugar-drug matrix” would be preferred, while the weight % of the "sugar-drug matrix" in the final formulation should be as small as possible.
  • the extent to which the two parameters can be adjusted is dependent on the maximum allowed size of the dosage form, e.g., 2 grams for capsules or tablets, that must be swallowed, and the dose to be administered.
  • the ratio of the at least one at least partially amorphous sugar, and drug of low aqueous solubility can range from about 1:10 to about 1000:1 such as from about 1:1 to about 600:1, or from about 5:1 to about 300:1, or from about 10:1 to about 100:1, and the weight % of the "sugar-drug matrix" in the final formulation can range from about 0.5% to about 99.5% such as from about 5% to about 99%.
  • drugs generally used at a relatively high dose e.g.
  • the weight ratio of the at least one at least partially amorphous sugar : drug can range from about 1.5:1 to about 10:1, preferably from about 2:1 to about 8 : 1 and more preferably from about 3 : 1 to about 6:1, and the weight % of the "sugar-drug matrix" in the final formulation can range from about 10 to about 99 weight %, preferably, from about 30 to about 95 weight % and, more preferably, from about 65 to about 90 weight %.
  • drugs generally used at a relatively low dose e.g.
  • the weight ratio of the at least one at least partially amorphous sugar: drug can be from about 1.5:1 to about 500:1, preferably from about 5:1 to about 50:1 and more preferably from about 10:1 to about 25:1, and the weight % of the "sugar-drug matrix" in the final formulation can range from about 10 to about 90 weight %, preferably, from about 15 to about 60 weight % and, more preferably, from about 20 to about 40 weight %.
  • an example of using a relatively high weight ratio of the at least one at least partially amorphous sugar to drug in the final formulation is about 6: 1 to about 4: 1 ; an example of a medium weight ratio of the at least one at least partially amorphous sugar to drug in the final formulation is about 3:1 to about 4:1, e.g., about 3.4:1; and an example of a relatively low weight ratio of the at least one at least partially amorphous sugar to drug in the final formulation is about 0.5:1 to less than about 3:1, e.g., about 0.66:1, about 1.5:1, and about 2.6:1.
  • an example of a relatively high weight % of the "drug-sugar matrix" in the final formulation is about 65 weight% to about 95 weight%, e.g., about 78 weight%; and an example of a relatively low weight% of the "drug-sugar matrix" in the final formulation is about 10 weight% to less than about 65 weight%, e.g., about 20 weight%, about 23.4 weight%, about 40 weight%, about 42.5 weight%, about 58 weight% and about 60 weight%.
  • the solubility of the drug obtained by this process can be controlled by controlling the temperature, mixing intensity and/or mixing time of the heated mass. All these parameters enable controlling the geometry and "architecture" of the resultant sugar-drug matrix, and consequently may control the extent to which the milling of the sugar-drug matrix effects the solubility of the drug particles.
  • the process of the invention can involve two main operations: 1) the formation of a homogeneous dispersion of the drug particles in a strong sugar matrix, and 2) strong milling of the sugar-drug matrix. These two operations result in fine particles, which yield good dissolution and consequently good absorption.
  • the mixing temperature and mixing time of the "hot mixing stage" e.g., step (a) of the first embodiment or step (V) of the second embodiment, of the drug and the at least one at least partially amorphous sugar.
  • the mixing temperature is below the melting point of the drug, no melting of the drug particles should occur and the mixing of the drug and sugar results in good dispersion of the drug particles in the sugar-drug matrix.
  • the mixing temperature is above the melting point of the drug, at least a portion of the drug particles in the heated mass should melt or be deformed (depending on the mixing temperature) resulting in even better dispersion of the drug in the sugar-drug matrix.
  • a third parameter which may have an effect on the final dispersion of the drug in the drug-sugar matrix is the mixing of the drug with the at least one at least partially amorphous sugar before the heating stage, e.g., step (a') of the second embodiment, or any optional mixing of the drug and the at least one at least partially amorphous sugar before step (a) of the first embodiment.
  • An example for the procedure for pre-mixing the drug and sugar comprises: I) direct mixing of the drug with the at least one at least partially amorphous sugar (with or without the addition of the surface active agent and dispersing agent, II) applying any other conventional or non-conventional granulation process which can improve the dispersion of drug particles to the product of step I) to form a pregranulated powder, and followed by III) using the pregranulated powder as a "drug source" in step (A) of the general process of the invention, step (a) of the first embodiment, or step (b') of the second embodiment.
  • the second operation of the above process involves strong milling of the final rigid sugar-drug matrix resulting in a break down of the rigid sugar-drug matrix into fine small particles. It is believed that the milling breaks down potential drug agglomerates, which are fixated across the breaking surfaces of the rigid sugar-drug matrix, an event which can further increase the solubility of the drug in the final blend. It is further believed that higher milling intensity would increase the efficiency of the milling and, consequently, would also increase the dissolution and absorption.
  • the desired dissolution rate is not always defined as “as fast as possible.” In certain circumstances, it is desired to control the rate at which the drug having low aqueous solubility, e.g., fenofibrate, is released by adjusting the parameters of the process of manufacture as above, or adjusting the content of the at least one at least partially amorphous sugar.
  • Example 1 CONTROL FOR COMPARISON
  • Formulation 1 (P00266) A fenofibrate tablet was made by conventional wet granulation based on the four steps described below. The ingredients in Table 1 were wet granulated and then compressed into tablets weighing 1368 mg. The dissolution profile of Formulation 1 in 1000 mL of 0.5% aqueous SLS solution, paddle (Apparatus II) at 50 rpm, was determined and compared with commercial versions of fenofibrate tablets ("old version" Tricor 160 mg and "newer version” Tricor 145 mg with supposedly increased dissolution and bioavailability).
  • Part I The blend of Part I was granulated by adding water (approx. 0.5 cc per unit dose), granules were dried at about 65°C and milled with a small laboratory scale mill (IKA® Maschinene GmbH & Co.) fitted with a 0.5mm aperture screen.
  • water approximately 0.5 cc per unit dose
  • granules were dried at about 65°C and milled with a small laboratory scale mill (IKA® Werke GmbH & Co.) fitted with a 0.5mm aperture screen.
  • the Part II ingredients were then blended with the granules of step 2 for about 2 minutes. 4.
  • the Part III ingredient was then blended with the blend of step 3 for about 2 minutes.
  • the final blend was compressed into capsule shaped tablets of 10mm/21mm dimensions.
  • Examples 2-7 display the effects of manipulating the parameters discussed above including, a high weight ratio of the at least one at least partially amorphous sugar to drug; a high weight % of the "drug-sugar matrix" in the final formulation; low or high mixing temperature and short or long mixing time.
  • a fenofibrate tablet weighing 1368 mg was made from the ingredients listed in Table 2 by the process of the invention.
  • Formulations 2-7 are examples of using a relatively high weight ratio (for the specified dose of 145 mg) of the at least one at least partially amorphous sugar to drug, e.g., about 6:1 to about 4:1; relatively high weight % of the "sugar-drug matrix" in the final formulation, e.g., about 65 to about 95 weight percent; low or high mixing temperatures; and short or long mixing time of the heated mass.
  • step 1 Powder of step 1 and ingredients of Part II were thoroughly blended.
  • the blend was transferred into a pot heated externally to a vessel wall temperature of Xl, and the blend was mixed while heated (the blend temperature, about X2, was measured by sticking a thermometer into the blended mass).
  • the mixing of the blend proceeded until the powder collapsed into a sticky mass in approximately 3 min, and then the sticky mass was mixed for an extra period of X3 minutes.
  • the mass was allowed to cool to room temperature (at approximately 20 0 C), and stored under dry conditions ( ⁇ 30% Relative Humidity) for about 1 hour. See the values of Xl, X2 and X3 in the Parameter Table. 3
  • the rigid mass of step 2 was milled using a FitzmillTM Communitor (2000 rpm, knives forward, 0.5 mm aperture screen).
  • the Part III ingredients were then mixed and then blended with the powder of step 3 for about 15 minutes. 5.
  • the Part IV ingredient was then blended with the powder of step 4 for about 5 minutes.
  • the final blend was compressed into capsule shaped tablets having dimensions of 10 mm/21 mm. Tablet hardness was found to be approximately 12-20 Strong-Cobb units (SCU).
  • Examples 8-10 exemplify a low weight ratio of the at least one at least partially amorphous sugar to total drug content in the finished dosage form - high temperature; short or long mixing time.
  • Fenofibrate tablets comprising a relatively low weight ratio of the at least one at least partially amorphous sugar to drug in the sugar-drug matrix (for a fenofibrate dose of 145 mg), i.e., from about 0.5:1 to about 1.5:1, can be prepared as per the process of the invention as described in Examples 2 through 7 using less sugar and thus the ratio of sugar to fenofibrate is decreased.
  • the milled sugar-drug matrix at the same or similar ratio of fenofibrate to the at least one at least partially amorphous sugar as produced by step 3 of the above process and then to add additional fenofibrate in the blending of step 4 to the step 3 materials, and continuing the process so as to achieve a total composition with ratio of the at least one at least partially amorphous sugar to total drug between about 0.5 : 1 to about 3 : 1 amorphous sugar in the finished dosage form.
  • formulations will similarly be influenced by the process conditions of temperature and time as described above when producing the hot blended mass. But overall it will be expected that those formulations comprising less amorphous sugar will have lower dissolution rates as compared to the formulations where all the fenofibrate is fixed within the sugar-drug matrix, i.e., all the fenofibrate is homogeneously dispersed in the sugar-drug matrix.
  • Formulations 8-10 are examples of employing low total contents of amorphous sugar.
  • the dissolution profiles of Formulation 8-10 can be determined in 1000 mL of 0.5% aqueous SLS solution, paddle (Apparatus II) at 50 rpm,
  • Ratio of amorphous sugar to total drug 0.66:1 (Formulation 8); 1.5:1 (Formulation 9);
  • Sucrose 80 (-14%) 180 (-25.6%) 310 (-35%)
  • step 1 and ingredients of Part II are thoroughly blended.
  • the blend is transferred into a pot heated externally to the set temperature, the blend is heated
  • the blend temperature is measured by sticking a thermometer into the blended mass.
  • the mixing proceeds until the powder collapses into a sticky mass, followed by extra predefined time of mixing the mass.
  • the mass is allowed to cool to room temp ( ⁇ 20° C), and stored under dry conditions ( ⁇ 30% Relative Humidity) for about 1 hour.
  • step 3 The rigid mass of step 2 is milled by using a FitzmillTM Communitor (2000 rpm, knives forward, 0.5 mm aperture screen). 4. The Part III ingredients, including the remaining fenofibrate are then blended with the powder of step 3 for about 15 minutes.
  • Part IV ingredient is then blended with the powder of step 4 for about five minutes.
  • Example 11 Formulation 11 (P-00260B3; medium ratio of amorphous sugar to drug: high temperature; long mixing time).
  • Fenofibrate tablets of the invention can also be prepared where the ratio of the amorphous sugar to fenofibrate in the sugar-drug matrix is lower than that in Examples 2 through 7 while ALL of the fenofibrate is fixed in the sugar-drug matrix.
  • the formulation exemplified in Example 11 is described as having a "medium ratio" (for the specified dose of 145 mg) of the amorphous sugar to drug, i.e., having a lower weight ratio of the at least one at least partially amorphous sugar to the drug than that used in formulations exemplified by Examples 2 through 7 which are examples of high weight ratio of the at least one at least partially amorphous sugar to the drug.
  • Fenofibrate tablets weighing 1095 mg were made from the ingredients listed in Table 5 by the process of the invention.
  • Formulation 11 is an examples in which a medium ratio (for the specified dose of 145 mg) of amorphous sugar to drug, i.e., about 3:1 to about 4:1; relatively high weight % of the "drug-sugar matrix" in the final formulation, e.g., about 65 to about 95% weight percent; high mixing temperatures and high mixing time of the heated mass were used.
  • step 1 Powder of step 1 and ingredients of Part II were thoroughly blended.
  • the blend was transferred into a pot heated externally to 170 C, and the blend was heated while mixing the blend (the temperature, which was measured by inserting the thermometer directly into the blended mass, was about 90° C).
  • the mixing proceeded until the powder collapsed into a sticky mass ( ⁇ 3 minutes), followed by extra 3 minutes of mixing the mass.
  • the mass was allowed to cool to room temperature (about 16° C), and stored under dry conditions ( ⁇ 30% relative humidity for about 1 hour ).
  • the rigid mass of step 2 was milled by using a FitzmillTM Communitor (2000 rpm , knives forward, 0.5 mm aperture screen).
  • Part III ingredients were then mixed and then blended with the powder of step 3 for about 15 minutes.
  • the final blend was compressed into capsule shaped tablets having dimensions of 10 mm/21mm.
  • Example 12 fP-002678 Formulations 12 - Different type of amorphous sugar, high ratio of amorphous sugar to drug; high weight % of the "drug-sugar matrix" in the final formulation Formulations of the invention can also be made from amorphous sugar that has been prepared without the use of glucose.
  • step 1 and ingredients of Part II were thoroughly blended.
  • the blend was transferred into a pot heated externally to 170° C, and the blend was heated while mixing (the blend temperature was measured by sticking a thermometer into the blended mass and was about 90° C).
  • the mixing proceeded until the powder collapsed into a sticky mass ( ⁇ 3 min), followed by extra 2 minutes of mixing the mass. After mixing the mass was allowed to cool to room temp (about 20° C), and stored under dry conditions ( ⁇ 30% RH for about 1 hour).
  • the rigid mass of step 2 was milled by a small laboratory scale mill (IKA® Maschinene GmbH & Co.) fitted with a 0.5 mm aperture screen. 4.
  • the Part III ingredients were then mixed and then blended with the powder of step 3 for about 15 minutes.
  • the Part IV ingredient was then blended with the powder of step 4 for about five minutes. 6.
  • the lubricated granules were compressed into capsule shaped tablets having dimensions of 10 mm/21 mm.
  • Example 13 (P00267)Formulations 13 Ccomparative; using entirely crystalline sugar instead of amorphous sugar - high temperature; long mixing time)
  • formulations of the invention are manufactured using a process that involves heating fenofibrate and amorphous sugar
  • a comparative example was performed wherein this same process was performed where the sugar used was in crystalline form and thus the preparatory step of producing the amorphous sugar was absent.
  • Fenofibrate tablets weighing 1368 mg were made from the ingredients listed in Table 7.
  • Formulations 13 is an example of using a relatively high content of crystalline sugar from about 50 weight % to about 99 weight %, employing high mixing temperatures and long mixing time (of the heated mass).
  • the dissolution profile of Formulation 13 in 1000 mL of 0.5% aqueous SLS solution, paddle (Apparatus II) at 50 rpm was tested and compared with commercial versions of Fenofibrate tablets ("Old version" Tricor 160 mg and "Newer version” Tricor 145 mg) (see dissolution rate study, below).
  • the Part III ingredient was then blended with the powder of step 3 for about five minutes. 5.
  • the lubricated blend was compressed into capsule shaped tablets of dimensions 12.0 mm x 5.5 mm.
  • Tablet hardness was found to be 9 Strong-Cobb units.
  • Example 14 fK-35211 Formulation 14 - Use of formulated granulate as a drug source in the "drug-sugar matrix", relatively high ratio of amorphous sugar to drug (for the specified dose of 145 mg), high weight % of the "sugar-drug- matrix” in the final formulation.
  • a fenofibrate tablet weighing 1444 mg was made from the ingredients listed in Table 8 by the process of the invention.
  • Formulation 14 is example of using a formulated granulate of fenofibrate as a drug source in the process for preparing the sugar-drug matrix.
  • this example used a relatively high ratio (for the specified dose of 145 mg) of the amorphous sugar to drug, e.g., about 6:1 to about 4:1; and a relatively high weight % of the "sugar- drug-matrix" in the final formulation, e.g., about 65 to about 95 weight %.
  • Part III ingredient was added to the rigid mass of stage 2 and together were milled with a FitzmillTM Communitor ( medium speed, knives forward, 2 to 0.5 mm aperture screen ).
  • Part IV ingredients were then mixed and then blended with the powder of stage 3 for about 15 minutes.
  • Part V ingredient was then blended with the powder of stage 4 for about 15 minutes.
  • the "granulated fenofibrate” was prepared according to the following procedures using the ingredients of Table 9.
  • Pruv (Sodium Stearyl Fumarate) 11 1.6
  • Lactose of Part II was dissolved in 192 mg of water heated to about 7O 0 C.
  • stage 1 was granulated by adding the lactose and SLS solutions of stage 2 and 3.
  • the granules were dried in a fluidized bed dryer (inlet air 55° C, outlet air not more than 40° C ) .
  • Aerosil of Part III was blended with the granules of stage 5 and then milled by FitzmillTM ( fitted with a 0.5 mm aperture screen).
  • the tablets were milled with a FitzmillTM Communitor ( knives forward, 0.5 mm aperture screen).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne entre autres un procédé de préparation d'une formulation pharmaceutique d'un médicament de faible solubilité dans l'eau, consistant à (A) fixer le médicament dans une matrice résistante comprenant au moins un sucre au moins partiellement amorphe pour obtenir une matrice sucre-médicament ; et (B) broyer la matrice sucre-médicament pour obtenir une matrice sucre-médicament broyée en tant que formulation pharmaceutique. L'invention concerne également la formulation pharmaceutique préparée par le procédé.
PCT/US2005/047260 2005-12-22 2005-12-22 Formes de dosage solides comprimées comprenant des médicaments de faible solubilité et procédé servant à les fabriquer Ceased WO2007073389A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
PCT/US2005/047260 WO2007073389A1 (fr) 2005-12-22 2005-12-22 Formes de dosage solides comprimées comprenant des médicaments de faible solubilité et procédé servant à les fabriquer
CNA2005800523342A CN101340896A (zh) 2005-12-22 2005-12-22 含有低溶解性药物的压缩的固体剂型和其制备方法
CA002626234A CA2626234A1 (fr) 2005-12-22 2005-12-22 Formes de dosage solides comprimees comprenant des medicaments de faible solubilite et procede servant a les fabriquer
IL190771A IL190771A0 (en) 2005-12-22 2008-04-10 Compressed solid dosage forms with drugs of low solubility and process for making the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2005/047260 WO2007073389A1 (fr) 2005-12-22 2005-12-22 Formes de dosage solides comprimées comprenant des médicaments de faible solubilité et procédé servant à les fabriquer

Publications (1)

Publication Number Publication Date
WO2007073389A1 true WO2007073389A1 (fr) 2007-06-28

Family

ID=36607362

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/047260 Ceased WO2007073389A1 (fr) 2005-12-22 2005-12-22 Formes de dosage solides comprimées comprenant des médicaments de faible solubilité et procédé servant à les fabriquer

Country Status (4)

Country Link
CN (1) CN101340896A (fr)
CA (1) CA2626234A1 (fr)
IL (1) IL190771A0 (fr)
WO (1) WO2007073389A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7799790B2 (en) 2006-07-20 2010-09-21 Helm Ag Amorphous aripiprazole and process for the preparation thereof
US7825125B2 (en) 2006-07-20 2010-11-02 Helm Ag Amorphous aripiprazole and process for the preparation thereof
WO2013065068A1 (fr) * 2011-11-01 2013-05-10 Genovo Development Services Limited Composition à désintégration orale d'agents antihistaminiques
US8865722B2 (en) 2006-01-05 2014-10-21 Teva Pharmaceutical Industries Ltd. Wet formulations of aripiprazole
WO2015152544A1 (fr) * 2014-03-31 2015-10-08 Hanmi Pharm. Co., Ltd. Dispersion solide amorphe comprenant un taxane, comprimé contenant la dispersion, et méthode de préparation associée

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104013589A (zh) * 2014-05-07 2014-09-03 万特制药(海南)有限公司 一种阿西替尼口腔崩解片及其制备方法
CN104337785A (zh) * 2014-11-04 2015-02-11 万全万特制药江苏有限公司 一种含有依折麦布的口腔崩解片及其制备方法
CN104546770A (zh) * 2015-01-07 2015-04-29 万特制药(海南)有限公司 一种阿齐沙坦的口腔崩解片及其制备方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002024193A1 (fr) * 2000-09-20 2002-03-28 Skyepharma Canada Inc. Microparticules de fibrate stabilisees
US20020119193A1 (en) * 2000-08-18 2002-08-29 Le Trang T. Oral fast-melt formulation of a cyclooxygenase-2 inhibitor
US20030032616A1 (en) * 1999-03-19 2003-02-13 Moskowitz Michael A. Increasing cerebral bioavailability of drugs
EP1314422A2 (fr) * 2001-11-14 2003-05-28 Scg, Inc. Préparations solides à désintegration orale et leur procédé de production
US6703369B1 (en) * 1999-09-13 2004-03-09 Hoffman-La Roche Inc. Lipase inhibiting compositions
US20050065183A1 (en) * 2003-07-31 2005-03-24 Indranil Nandi Fexofenadine composition and process for preparing
WO2006016125A1 (fr) * 2004-08-12 2006-02-16 Reckitt Benckiser Healthcare (Uk) Limited Granules composes de « a ains » et d’un polyol fabrique par extrusion de matiere fondue

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030032616A1 (en) * 1999-03-19 2003-02-13 Moskowitz Michael A. Increasing cerebral bioavailability of drugs
US6703369B1 (en) * 1999-09-13 2004-03-09 Hoffman-La Roche Inc. Lipase inhibiting compositions
US20020119193A1 (en) * 2000-08-18 2002-08-29 Le Trang T. Oral fast-melt formulation of a cyclooxygenase-2 inhibitor
WO2002024193A1 (fr) * 2000-09-20 2002-03-28 Skyepharma Canada Inc. Microparticules de fibrate stabilisees
EP1314422A2 (fr) * 2001-11-14 2003-05-28 Scg, Inc. Préparations solides à désintegration orale et leur procédé de production
US20050065183A1 (en) * 2003-07-31 2005-03-24 Indranil Nandi Fexofenadine composition and process for preparing
WO2006016125A1 (fr) * 2004-08-12 2006-02-16 Reckitt Benckiser Healthcare (Uk) Limited Granules composes de « a ains » et d’un polyol fabrique par extrusion de matiere fondue

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8865722B2 (en) 2006-01-05 2014-10-21 Teva Pharmaceutical Industries Ltd. Wet formulations of aripiprazole
US7799790B2 (en) 2006-07-20 2010-09-21 Helm Ag Amorphous aripiprazole and process for the preparation thereof
US7825125B2 (en) 2006-07-20 2010-11-02 Helm Ag Amorphous aripiprazole and process for the preparation thereof
WO2013065068A1 (fr) * 2011-11-01 2013-05-10 Genovo Development Services Limited Composition à désintégration orale d'agents antihistaminiques
WO2015152544A1 (fr) * 2014-03-31 2015-10-08 Hanmi Pharm. Co., Ltd. Dispersion solide amorphe comprenant un taxane, comprimé contenant la dispersion, et méthode de préparation associée
US9867801B2 (en) 2014-03-31 2018-01-16 Hanmi Pharm. Co., Ltd. Amorphous solid dispersion comprising taxane, tablet comprising the same, and method for preparing the same

Also Published As

Publication number Publication date
CN101340896A (zh) 2009-01-07
CA2626234A1 (fr) 2007-06-28
IL190771A0 (en) 2008-11-03

Similar Documents

Publication Publication Date Title
JP5794650B2 (ja) 難溶性薬物の溶解性改善製剤
KR101468738B1 (ko) 경구 용량 형태
KR20100126452A (ko) 난용성 약물용 약학적 조성물
JP2009051852A (ja) ナテグリニド含有製剤
KR20230107902A (ko) Cgrp-활성 화합물에 대한 정제 제제
JP2008540644A (ja) 新規粒質化方法及びそれから生成される粒質物
WO2007073389A1 (fr) Formes de dosage solides comprimées comprenant des médicaments de faible solubilité et procédé servant à les fabriquer
US20070014854A1 (en) Novel granulation process
JP5511663B2 (ja) タムスロシン塩酸塩を含有する球形微粒子の製造方法
US20070148245A1 (en) Compressed solid dosage forms with drugs of low solubility and process for making the same
US20240390285A1 (en) High-dose compressible dosage forms manufactured by simultaneous melt-coating and melt-granulation of active pharmaceutical ingredients
JP5651478B2 (ja) 糖アルコールと共微粒子化されたエンタカポンの医薬組成物
EP1808163A1 (fr) Formes galéniques solides comprimées avec des principes actifs de faible solubilité et leur procédé de fabrication
JP2021167306A (ja) 崩壊性粒子の製造方法
HK1104796A (en) Compressed solid dosage forms with drugs of low solubility and process for making the same
WO2020208230A1 (fr) Préparations de dosage de comprimé d'une phosphocholine d'oléyle
AU2012101355B4 (en) Oral dosage form
US20230114357A1 (en) Continuous melt-coating of active pharmaceutical ingredients using surfactants for dissolution enhancement
JP4993274B2 (ja) フェノフィブラート含有製剤組成物の製造方法
JP6506810B2 (ja) フェノフィブラートの固体分散体
JP2011513328A (ja) バルサルタン固体経口投薬形態及びそのような製剤を製造する方法

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200580052334.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 190771

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2626234

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 4349/DELNP/2008

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05855768

Country of ref document: EP

Kind code of ref document: A1